Pengguguran perubatan
| Latar belakang | |
|---|---|
| Jenis pengguguran | Perubatan |
| Penggunaan pertama | Amerika Syarikat 1979 (karboprost), Jerman Selatan 1981 (sulprostone), Jepun 1984 (gemeprost), Perancis 1988 (mifepristone), Amerika Syarikat 1988 (misoprostol) |
| Tempoh kehamilan | 3–24+ minggu |
| Penggunaan | |
| Pengguguran perubatan sebagai peratusan dari semua pengguguran | |
| Perancis | 64% (2016) |
| Sweden | 92% (2016) |
| UK: Eng. & Wales | 62% (2016) |
| UK: Scotland | 83% (2016) |
| Amerika Syarikat | 39% (2017) |
| Infobox references | |
| Kombinasi | |
|---|---|
| Mifepriston | Modulator reseptor progesteron |
| Misoprostol | Prostaglandin |
| Data klinikal | |
| Nama dagang | Mifegymiso,[1] Medabon Combipack |
| Kod ATC | |
| Status perundangan | |
| Status perundangan | |
Pengguguran perubatan, berlaku apabila ubat-ubatan yang ditetapkan secara perubatan ( ubat ) digunakan untuk menyebabkan pengguguran. Rejimen khas terdiri daripada gabungan ubat-ubatan, dengan mifepriston diikuti dengan misoprostol sebagai rejimen abortifasien paling biasa.[4] Mifepriston diikuti dengan misoprostol untuk pengguguran dianggap selamat dan berkesan sepanjang usia kehamilan.[5] Apabila mifepristone tidak tersedia, misoprostol sahaja boleh digunakan. Selain mifepriston/misoprostol, ubat lain boleh digunakan bergantung pada ketersediaan dan pertimbangan khusus pesakit.
Prosedur perubatan untuk mendorong pengguguran secara fizikal yang tidak menggunakan ubat secara amnya disebut sebagai pengguguran pembedahan.
Rujukan
[sunting | sunting sumber]- ^ "Mifegymiso Product Monograph" (PDF). Health Canada.
- ^ "Medabon - Combipack of Mifepristone 200 mg tablet and Misoprostol 4 x 0.2 mg vaginal tablets - Summary of Product Characteristics (SmPC)". (emc). 3 February 2020. Dicapai pada 19 January 2021.
- ^ https://www.ema.europa.eu/documents/psusa/mifepristone/misoprostol-list-nationally-authorised-medicinal-products-psusa/00010378/202005_en.pdf
- ^ Medical management of abortion. World Health Organization. Geneva, Switzerland. January 30, 2019. m/s. 24. ISBN 978-9241550406. OCLC 1084549520.CS1 maint: others (link)
- ^ Safe abortion: technical and policy guidance for health systems-2nd ed. Italy: WHO. 2012. m/s. 42. ISBN 9789241548434.
Pautan luar
[sunting | sunting sumber]- WHO Scientific Group on Medical Methods for Termination of Pregnancy (December 1997). Medical methods for termination of pregnancy. Technical Report Series, No. 871. Geneva: World Health Organization. ISBN 978-92-4-120871-0. WARNING: LINK GIVES ONLY THE FIRST PAGE OF THE REPORT; THE REST IS LISTED AS "OUT OF PRINT"
- Royal College of Obstetricians and Gynaecologists (November 23, 2011). The care of women requesting induced abortion. Evidence-based clinical guideline number 7 (PDF) (ed. 3rd rev.). London: RCOG Press. Diarkibkan daripada yang asal (PDF) pada May 29, 2012.
- ICMA (2013). "ICMA Information Package on Medical Abortion". Chișinău, Moldova: International Consortium for Medical Abortion (ICMA).
- The official protocol of the clinical trial of the "reversal" regimen is here: Ujian klinikal bernombor NCT03774745 bagi "Blocking Mifepristone Action With Progesterone" di ClinicalTrials.gov
Kategori:
- Drugs with non-standard legal status
- Infobox rencana dadah dengan tajuk infobox tidak lalai
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Kesuburan
- Kaedah pengguguran
- Dadah dengan status undang-undang tidak piawai